Stockreport

Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live'25 [Yahoo! Finance]

Chemomab Therapeutics Ltd. - American Depositary Shares  (CMMB) 
PDF Treatment with Nebokitug Is Well-Tolerated and Associated with Substantial Improvements in Multiple Fibrotic and Inflammatory Biomarkers that Represent Slowing of PSC D [Read more]